5.08

4.51% -0.24

Oric Pharmaceuticals Inc (ORIC)

Overview News Price History Option Chain Financials Discussions Forecast

Oric Pharmaceuticals Inc stock is traded at $5.08, with a volume of 418.64K. It is down -4.51% in the last 24 hours and up +8.32% over the past month. ORIC Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It has a pipeline of therapies designed to counter resistance mechanisms in cancer by leveraging its expertise within three specific areas: hormone-dependent cancers, precision oncology, and key tumor dependencies. The company has product candidates namely ORIC-944, ORIC-114, and ORIC-533. The Company has as one operating segment, focused on the discovery and development of therapies designed to counter the resistance mechanisms in cancer.

Previous Close:

$5.32

Open:

$5.34

24h Volume:

418.64K

Relative Volume:

0.42

Market Cap:

$403.07M

Revenue:

Net Income/Loss:

$-119.87M

P/E Ratio:

-2.8066

EPS:

-1.81

Net Cash Flow:

$-109.90M

1W Performance:

-10.41%

1M Performance:

+8.32%

6M Performance:

-50.49%

1Y Performance:

-46.53%

1-Day Range:

$5.04

$5.59

1-Week Range:

$4.52

$5.83

52-Week Range:

$3.8951

$14.67

Oric Pharmaceuticals Inc Stock (ORIC) Company Profile

Name

Oric Pharmaceuticals Inc

Sector

Healthcare (1153)

Industry

Biotechnology (676)

Phone

(650) 388-5600

Address

240 E. GRAND AVE., SOUTH SAN FRANCISCO, CA

Employee

122

Twitter

Next Earnings Date

2024-11-04

Latest SEC Filings

ORIC's Discussions on Twitter

Compare ORIC with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
ORIC Oric Pharmaceuticals Inc	5.08	403.07M	0	-119.87M	-109.90M	-1.81
VRTX Vertex Pharmaceuticals Inc	424.99	128.84B	11.10B	-988.90M	-1.26B	-3.92
REGN Regeneron Pharmaceuticals Inc	527.78	65.38B	14.09B	4.50B	2.96B	39.28
ARGX Argen X Se Adr	549.65	39.67B	2.19B	833.04M	-1.28B	12.71
ALNY Alnylam Pharmaceuticals Inc	251.15	33.82B	2.35B	-269.70M	-75.39M	-2.09
ONC Beigene Ltd Adr	231.99	27.60B	3.81B	-644.79M	-669.77M	-6.24

Oric Pharmaceuticals Inc Stock (ORIC) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Oct-31-24	Initiated	Wells Fargo	Overweight
Sep-06-24	Initiated	Stifel	Buy
Feb-23-24	Initiated	Cantor Fitzgerald	Overweight
Sep-22-23	Initiated	Wedbush	Outperform
Mar-23-23	Upgrade	H.C. Wainwright	Neutral → Buy
Mar-21-23	Upgrade	Guggenheim	Neutral → Buy
Mar-16-23	Upgrade	Oppenheimer	Perform → Outperform
Jul-18-22	Resumed	Oppenheimer	Perform
Apr-04-22	Upgrade	Citigroup	Neutral → Buy
Mar-25-22	Downgrade	H.C. Wainwright	Buy → Neutral
Mar-22-22	Downgrade	Citigroup	Buy → Neutral
Mar-22-22	Downgrade	Guggenheim	Buy → Neutral
Mar-22-22	Downgrade	Oppenheimer	Outperform → Perform
Jul-06-21	Upgrade	Citigroup	Neutral → Buy
Jan-25-21	Downgrade	Citigroup	Buy → Neutral
Aug-13-20	Initiated	Robert W. Baird	Outperform
Aug-06-20	Upgrade	Citigroup	Neutral → Buy
Aug-03-20	Initiated	H.C. Wainwright	Buy
May-19-20	Initiated	Citigroup	Neutral
May-19-20	Initiated	Guggenheim	Buy
May-19-20	Initiated	JP Morgan	Overweight
May-19-20	Initiated	Jefferies	Buy

View All

Oric Pharmaceuticals Inc Stock (ORIC) Latest News

10:23 AM

Q2 EPS Forecast for ORIC Pharmaceuticals Raised by Analyst - MarketBeat

10:23 AM

May 09, 2025

ORIC Pharmaceuticals (ORIC) Receives Increased Price Target from H.C. Wainwright | ORIC Stock News - GuruFocus

May 09, 2025

ORIC Pharmaceuticals (ORIC) Price Target Raised by Analyst | ORIC Stock News - GuruFocus

May 09, 2025

Wedbush Boosts Earnings Estimates for ORIC Pharmaceuticals - Defense World

May 09, 2025

May 08, 2025

Price T Rowe Associates Inc. MD Has $10.45 Million Holdings in ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) - MarketBeat

May 08, 2025

Schonfeld Strategic Advisors LLC Takes $5.85 Million Position in ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) - MarketBeat

May 08, 2025

Oppenheimer Cuts ORIC Pharmaceuticals (NASDAQ:ORIC) Price Target to $12.00 - MarketBeat

May 08, 2025

Cantor Fitzgerald Reiterates "Overweight" Rating for ORIC Pharmaceuticals (NASDAQ:ORIC) - MarketBeat

May 08, 2025

May 07, 2025

ORIC Pharmaceuticals (NASDAQ:ORIC) Issues Quarterly Earnings Results - MarketBeat

May 07, 2025

1,732,571 Shares in ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) Bought by Boxer Capital Management LLC - MarketBeat

May 07, 2025

Ratio Review: Analyzing ORIC Pharmaceuticals Inc (ORIC)’s Price-to-Cash and Price-to-Free Cash Flow - DWinneX

May 07, 2025

ORIC Pharmaceuticals' (ORIC) "Buy" Rating Reiterated at HC Wainwright - MarketBeat

May 07, 2025

MetLife Investment Management LLC Has $336,000 Stake in ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) - Defense World

May 07, 2025

ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) Shares Purchased by Wells Fargo & Company MN - Defense World

May 07, 2025

ORIC Pharmaceuticals Reports Q1 2025 Progress and Plans - TipRanks

May 07, 2025

May 06, 2025

ORIC Pharmaceuticals (ORIC) Target Price Lowered by Oppenheimer | ORIC Stock News - GuruFocus

May 06, 2025

ORIC Pharmaceuticals (ORIC) Receives Reiterated "Overweight" Rat - GuruFocus

May 06, 2025

Oppenheimer Adjusts Price Target on ORIC Pharmaceuticals to $12 From $15, Maintains Outperform Rating - marketscreener.com

May 06, 2025

Oppenheimer Revises Price Target for ORIC Following Quarterly Re - GuruFocus

May 06, 2025

Barclays PLC Grows Holdings in ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) - Defense World

May 06, 2025

ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) Shares Sold by Adage Capital Partners GP L.L.C. - MarketBeat

May 06, 2025

ORIC Pharmaceuticals’ (ORIC) Buy Rating Reaffirmed at HC Wainwright - Defense World

May 06, 2025

May 05, 2025

ORIC Pharmaceuticals Inc Reports Q1 2025 Earnings: EPS Misses Estimate at -0.51, Revenue Remains at $0 Million - GuruFocus

May 05, 2025

Oric Pharmaceuticals Inc reports results for the quarter ended March 31Earnings Summary - TradingView

May 05, 2025

Oric Pharmaceuticals, Inc. SEC 10-Q Report - TradingView

May 05, 2025

ORIC® Pharmaceuticals Reports First Quarter 2025 Financial Results and Operational Updates - GlobeNewswire

May 05, 2025

ORIC Pharma Secures Major J&J Partnership, Reports 5 Clinical Readouts Coming in Cancer Drug Pipeline - Stock Titan

May 05, 2025

Invesco Ltd. Grows Holdings in ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) - Defense World

May 05, 2025

ORIC Pharmaceuticals (ORIC) Rating Reiterated at HC Wainwright & Co. | ORIC Stock News - GuruFocus

May 05, 2025

May 04, 2025

ORIC Pharmaceuticals (ORIC) to Release Quarterly Earnings on Monday - Defense World

May 04, 2025

May 03, 2025

(ORIC) Long Term Investment Analysis - news.stocktradersdaily.com

May 03, 2025

May 02, 2025

ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) | ORIC Stock News - GuruFocus

May 02, 2025

ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - The Manila Times

May 02, 2025

Oncology Biotech ORIC Issues Major Equity Package: 32,400 Options Plus RSUs for New Talent - Stock Titan

May 02, 2025

An analyst sees good growth prospects for ORIC Pharmaceuticals Inc (ORIC) - Sete News

May 02, 2025

Market Watch: ORIC Pharmaceuticals Inc (ORIC)’s Noteworthy Drop, Closing at 5.57 - DWinneX

May 02, 2025

May 01, 2025

Is ORIC Pharmaceuticals Inc (ORIC) worth investing in despite its overvalued state? - uspostnews.com

May 01, 2025

ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) Shares Sold by Legal & General Group Plc - Defense World

May 01, 2025

Apr 30, 2025

ORIC Pharmaceuticals Inc’s Shares Reel: -51.58% Quarterly Revenue Decline Amid 401.98M Market Cap - investchronicle.com

Apr 30, 2025